Monopar Therapeutics (MNPR) EPS (Basic) (2017 - 2019)
Historic EPS (Basic) for Monopar Therapeutics (MNPR) over the last 3 years, with Q4 2019 value amounting to -$0.13.
- Monopar Therapeutics' EPS (Basic) fell 3140.97% to -$0.13 in Q4 2019 from the same period last year, while for Sep 2020 it was -$0.11, marking a year-over-year increase of 7456.53%. This contributed to the annual value of -$0.46 for FY2019, which is 3253.24% down from last year.
- Monopar Therapeutics' EPS (Basic) amounted to -$0.13 in Q4 2019, which was down 3140.97% from -$0.08 recorded in Q3 2019.
- In the past 5 years, Monopar Therapeutics' EPS (Basic) ranged from a high of -$0.04 in Q1 2017 and a low of -$1.68 during Q3 2017
- Moreover, its 3-year median value for EPS (Basic) was -$0.09 (2018), whereas its average is -$0.22.
- Over the last 5 years, Monopar Therapeutics' EPS (Basic) had its largest YoY gain of 9572.36% in 2018, and its largest YoY loss of 12500.0% in 2018.
- Monopar Therapeutics' EPS (Basic) (Quarter) stood at -$0.05 in 2017, then crashed by 100.0% to -$0.1 in 2018, then tumbled by 31.41% to -$0.13 in 2019.
- Its EPS (Basic) stands at -$0.13 for Q4 2019, versus -$0.08 for Q3 2019 and -$0.1 for Q2 2019.